ReviewCurrent osteoporosis reports2014
Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment.
Review in Current osteoporosis reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Pooled it
- Immune-mediated platelet refractoriness: Mechanisms, diagnostics, and therapeutic breakthroughs.Transfusion medicine (Oxford, England) · 2026Review
- Spectrum of Osteoporosis Etiologies with Associated Vertebral Compression Fractures in Children: Analysis of 11 Cases.Journal of clinical medicine · 2025Article
- Thyroid nodules in children and adolescents: Investigation and management.Journal of paediatrics and child health · 2022Review
- Evaluating and optimizing bone health in children with chronic health conditions.Paediatrics & child health · 2022Article
- L'évaluation et l'optimisation de la santé osseuse chez les enfants ayant des affections chroniques.Paediatrics & child health · 2022Article
- Bone Health in Children with Rheumatic Disorders: Focus on Molecular Mechanisms, Diagnosis, and Management.International journal of molecular sciences · 2022Review
- Article
- Bone morbidity in pediatric acute lymphoblastic leukemia.Annals of pediatric endocrinology & metabolism · 2020Article
- Risk factors for nonunion of bone fracture in pediatric patients: An inception cohort study of 237,033 fractures.Medicine · 2018Article
- Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study.Pediatric rheumatology online journal · 2018Article
- Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.Paediatric drugs · 2017Review
- Bone modeling, remodeling, and skeletal health in children and adolescents: mineral accrual, assessment and treatment.Annals of pediatric endocrinology & metabolism · 2017Review
- Peripheral quantitative computed tomography (pQCT) for the assessment of bone strength in most of bone affecting conditions in developmental age: a review.Italian journal of pediatrics · 2016Review
- Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children.Scientific reports · 2016Article
- Update on Bone Health in Pediatric Chronic Disease.Endocrinology and metabolism clinics of North America · 2016Review
- Vitamin D—update for the pediatric rheumatologists.Pediatric rheumatology online journal · 2015Review
- The molecular etiology and treatment of glucocorticoid-induced osteoporosis.Tzu chi medical journalReview
- GLUCOCORTICOID-INDUCED BONE DISEASE: MECHANISMS AND IMPORTANCE IN PEDIATRIC PRACTICE.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao PauloReview
Corrections and comments
- Erratum issuedStefano, Stagi [corrected to Stagi, Stefano]
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Children with chronic illnesses such as Juvenile Idiopathic Arthritis and Crohn's disease, particularly when taking glucocorticoids, are at significant risk for bone fragility. Furthermore, when childhood illness interferes with achieving normal peak bone mass, life-long fracture risk is increased. Osteopenia and osteoporosis, which is increasingly recognized in pediatric chronic disease, likely results from numerous disease- and treatment-related factors, including glucocorticoid exposure. Diagnosing osteoporosis in childhood is complicated by the limitations of current noninvasive techniques such as DXA, which despite its limitations remains the gold standard. The risk:benefit ratio of treatment is confounded by the potential for spontaneous restitution of bone mass deficits and reshaping of previously fractured vertebral bodies. Bisphosphonates have been used to treat secondary osteoporosis in children, but limited experience and potential long-term toxicity warrant caution in routine use. This article reviews the factors that influence loss of normal bone strength and evidence for effective treatments, in particular in patients with gastrointestinal and rheumatologic disorders who are receiving chronic glucocorticoid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.